Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: A pilot study

Clinical Nephrology

Volumn 80, Issue 1, 2013, Pages 1-8

  Lemos, Marcelo M ^a   Watanabe, Renato ^a   Carvalho, Aluízio B ^a   Jancikic, Alessandra D B ^a   Sanches, Fabiana M R ^a   Christofalo, Dejaldo M ^a   Draibe, Sérgio A ^a   Canziani, Maria Eugênia F ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

CKD; Nondialysis patients; Rosuvastatin; Sevelamer; Vascular calcification

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SEVELAMER;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OPEN STUDY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TABLET; TREATMENT DURATION;

ADULT; AGED; ANALYSIS OF VARIANCE; CALCINOSIS; CHELATING AGENTS; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PILOT PROJECTS; POLYAMINES; PYRIMIDINES; RENAL INSUFFICIENCY, CHRONIC; SULFONAMIDES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84880685770     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107630     Document Type: Article

References (27)

1. Culleton BF, Larson MG, Wilson PWF, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999; 56: 2214-2219.
2. Watanabe R, Lemos MM, Manfredi SR, Draibe SA, Canziani ME. Impact of cardiovascular calcification in nondialyzed patients after 24 months of followup. Clin J Am Soc Nephrol. 2010; 5: 189-194.
3. Russo D, Corrao S, Battaglia Y, Andreucci M, Caiazza A, Carlomagno A, Lamberti M, Pezone N, Pota A, Russo L, Sacco M, Scognamiglio B. Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis. Kidney Int. 2011; 80: 112-118.
4. O'Neill WC, Sigrist MK, McIntyre CW. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant. 2010; 25: 187-191.
5. McCullough PA, Agrawal V, Danielewicz E, Abela GS. Accelerated atherosclerotic calcification and Monckeberg's sclerosis: a continuum of advanced vascular pathology in chronic kidney disease. Clin J Am Soc Nephrol. 2008; 3: 1585-1598.
6. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353: 238-248.
7. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G et al; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360: 1395-1407.
8. Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003; 361: 2024-2031.
9. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B et al; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377: 2181-2192.
10. Holdaas H, Holme I, Schmieder RE, Jardine AG, Zannad F, Norby GE, Fellström BC; AURORA study group. Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol. 2011; 22: 1335-1341.
11. Boaz M, Katzir Z, Schwartz D, Gafter U, Biro A, Shtendik L, Kon V, Chernin G, Weinstein T. Effect of sevelamer hydrochloride exposure on carotid intima media thickness in hemodialysis patients. Nephron Clin Pract. 2011; 117: c83-c88.
12. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007; 71: 438-441.
13. Barreto DV, Barreto FC, de Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, Moyses RM, Neves KR, Jorgetti V, Miname M, Santos RD, Canziani ME. Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study. Nephron Clin Pract. 2008; 110: c273-c283.
14. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245-252.
15. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005; 68: 1815-1824.
16. Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, Russo L, Scafarto A, Andreucci VE. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007; 72: 1255-1261.
17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150: 604-612.
18. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; S1-S130.
19. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15: 827-832.
20. Achenbach S, Ropers D, Pohle K, Leber A, Thilo C, Knez A, Menendez T, Maeffert R, Kusus M, Regenfus M, Bickel A, Haberl R, Steinbeck G, Moshage W, Daniel WG. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation. 2002; 106: 1077-1082.
21. Nitta K, Akiba T, Nihei H. Colestimide co-administered with atorvastatin attenuates the progression of vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2004; 19: 215.
22. Arad Y, Spadaro LA, Roth M, Newstein D, Guerci AD. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol. 2005; 46: 166-172.
23. Houslay ES, Cowell SJ, Prescott RJ, Reid J, Burton J, Northridge DB, Boon NA, Newby DE; Scottish Aortic Stenosis and Lipid Lowering Therapy, Impact on Regression trial Investigators. Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial. Heart. 2006; 92: 1207-1212.
24. Henein MY, Owen A. Statins moderate coronary stenoses but not coronary calcification: Results from meta-analyses. Int J Cardiol. 2010. Epub ahead of print.
25. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006; 295: 1556-1565.
26. Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, Budoff M; CARE-2 Investigators. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008; 51: 952-965.
27. Brezina B, Qunibi WY, Nolan CR. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int Suppl. 2004; 66 (s90): S39-S45.